Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia

This early-phase study tests whether adding an experimental drug called Q702 to a standard two-drug combination (azacitidine and venetoclax) is safe and effective in patients with acute myeloid leukemia (AML) — a blood cancer — that has relapsed or stopped responding to previous treatment. **You may be eligible if...** - You are 18 or older with confirmed AML (or a related condition called MDS/AML) that has relapsed or not responded to prior treatment - You have no remaining standard treatment options - You are in good general health (ECOG 0–1) - If you relapsed after a stem cell transplant, you have recovered from transplant-related complications and are off immunosuppression **You may NOT be eligible if...** - You have acute promyelocytic leukemia (a specific subtype of AML) - You have active or uncontrolled infection, or severe organ problems - Your prior remission lasted less than 12 months and you are younger than 60 (unless you have certain high-risk features) Talk to your doctor to see if this trial is right for you.